EJC Supplements
Volume 9, Issue 2 , Pages 5-10 , October 2011

Anthracyclines in the adjuvant treatment of breast cancer: state of the art

  • Monica N. Fornier

      Affiliations

    • Corresponding Author InformationCorrespondence: Monica N. Fornier, Evelyn H. Lauder Breast Center, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Tel.: +1 646 888 4563; fax: +1 646 888 4555

References 

  1. Early Breast Cancer Trialists' Collaborative Group . Polychemotherapy for early breast cancer: an overview of the randomised trials . Lancet . 1998;352:930–942
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet . 2005;365:1687–1717
  3. Gianni L , Norton L , Wolmark N , Suter TM , Bonadonna G , Hortobagyi GN . Role of anthracyclines in the treatment of early breast cancer . J Clin Oncol . 2009;27:4798–4808
  4. Pinder MC , Duan Z , Goodwin JS , Hortobagyi GN , Giordano SH . Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer . J Clin Oncol . 2007;25:3808–3815
  5. Muss HB , Berry DA , Cirrincione C , et al.   Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience . J Clin Oncol . 2007;25:3699–3704
  6. Fisher B , Brown AM , Dimitrov NV , et al.   Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 . J Clin Oncol . 1990;8:1483–1496
  7. Levine MN , Bramwell VH , Pritchard KI , et al.   Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group . J Clin Oncol . 1998;16:2651–2658
  8. Jones S , Holmes FA , O'Shaughnessy J , et al.   Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 . J Clin Oncol . 2009;27:1177–1183
  9. Muss HB , Thor AD , Berry DA , et al.   c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer . N Engl J Med . 1994;330:1260–1266
  10. Paik S , Bryant J , Park C , et al.   erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer . J Natl Cancer Inst . 1998;90:1361–1370
  11. Pritchard KI , Shepherd LE , O'Malley FP , et al.   HER2 and responsiveness of breast cancer to adjuvant chemotherapy . N Engl J Med . 2006;354:2103–2111
  12. Gennari A , Sormani MP , Pronzato P , et al.   HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials . J Natl Cancer Inst . 2008;100:14–20
  13. Oakman C , Moretti E , Di Leo A . Re-searching anthracycline therapy . Breast Cancer Res Treat . 2010;123:171–175
  14. Slamon D , Eiermann W , Robert N , et al.   Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study . Breast Cancer Res Treat . 2005;94(Suppl 1):S5
  15. Slamon D , Eiermann W , Robert N , et al.   BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients . Breast Cancer Res Treat . 2006;100(Suppl 1): abs 52.
  16. O'Malley FP , Chia S , Tu D , et al.   Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy . J Natl Cancer Inst . 2009;101:644–650
  17. McArthur HL , Tan LK , Patil S , et al.   High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOP2A and HER2 coamplification is uncommon in human breast cancer . Cancer Res . 2009;69(Meeting Abstract Supplement): abs 2023.
  18. Di Leo A , Isola J , Piette F , et al.   A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy . Breast Cancer Res Treat . 2008;107(Suppl):705
  19. Desmedt C , Di Leo A , de Azambuja E , et al.   Multifactorial approach to predicting resistance to anthracyclines . J Clin Oncol . 2011;29:1578–1586
  20. Rouzier R , Pérou CM , Symmans WF , et al.   Breast cancer molecular subtypes respond differently to preoperative chemotherapy . Clin Cancer Res . 2005;11:5678–5685
  21. Cheang M , Chia SK , Tu S , et al.   Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEE . J Clin Oncol . 2009;27(Suppl 15S):519

PII: S1359-6349(11)70003-9

doi: 10.1016/S1359-6349(11)70003-9

EJC Supplements
Volume 9, Issue 2 , Pages 5-10 , October 2011

Article Tools